| Ulcerative Colitis
Omvoh vs Humira
Side-by-side clinical, coverage, and cost comparison for ulcerative colitis.Deep comparison between: Omvoh vs Humira with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsHumira has a higher rate of injection site reactions vs Omvoh based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Humira but not Omvoh, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Omvoh
Humira
At A Glance
IV infusion / SC injection
Every 4 weeks
IL-23 antagonist
SC injection
Every other week
TNF-alpha antagonist
Indications
- Ulcerative Colitis
- Crohn Disease
- Rheumatoid Arthritis
- Juvenile arthritis
- Arthritis, Psoriatic
- Ankylosing spondylitis
- Crohn Disease
- Ulcerative Colitis
- Chronic small plaque psoriasis
- Hidradenitis Suppurativa
- Uveitis
Dosing
Ulcerative Colitis Induction: 300 mg IV infusion at Weeks 0, 4, and 8; Maintenance: 200 mg SC injection every 4 weeks starting Week 12.
Crohn Disease Induction: 900 mg IV infusion at Weeks 0, 4, and 8; Maintenance: 300 mg SC injection every 4 weeks starting Week 12.
Rheumatoid Arthritis, Arthritis, Psoriatic, Ankylosing spondylitis 40 mg SC every other week; some RA patients not receiving MTX may increase to 40 mg every week or 80 mg every other week.
Juvenile arthritis, Uveitis (pediatric) Weight-based SC dosing every other week: 10 mg (10 kg to <15 kg), 20 mg (15 kg to <30 kg), or 40 mg (>=30 kg) for patients 2 years of age and older.
Crohn Disease 160 mg SC on Day 1 (in one day or split over two consecutive days), 80 mg on Day 15, then 40 mg every other week starting Day 29.
Ulcerative Colitis 160 mg SC on Day 1 (in one day or split over two consecutive days), 80 mg on Day 15, then 40 mg every other week starting Day 29; discontinue if no clinical remission by 8 weeks (Day 57).
Chronic small plaque psoriasis, Uveitis 80 mg SC initial dose, then 40 mg every other week starting 1 week after the initial dose.
Hidradenitis Suppurativa 160 mg SC on Day 1 (in one day or split over two consecutive days), 80 mg on Day 15, then 40 mg every week or 80 mg every other week starting Day 29.
Contraindications
- Previous serious hypersensitivity reaction to mirikizumab-mrkz or any excipient
—
Adverse Reactions
Most common (>=2%) - Ulcerative Colitis Upper respiratory tract infections, injection site reactions, arthralgia, rash, headache, herpes viral infection
Most common (>=5%) - Crohn Disease Upper respiratory tract infections, injection site reactions, headache, arthralgia, elevated liver tests
Serious Intestinal sepsis, listeria sepsis, pneumonia, abscess, cellulitis, sepsis
Most common (>=5%) Injection site reactions, upper respiratory infection, headache, rash, accidental injury, sinusitis, urinary tract infection, nausea, hyperlipidemia, abdominal pain, flu syndrome, hypercholesterolemia, back pain.
Serious Serious infections (pneumonia, septic arthritis, prosthetic and post-surgical infections, erysipelas, cellulitis, diverticulitis, pyelonephritis), tuberculosis, opportunistic infections, malignancies, severe hepatic reactions including acute liver failure, new-onset lupus-like syndrome.
Postmarketing Diverticulitis, large bowel perforations, pancreatitis, liver failure, autoimmune hepatitis, sarcoidosis, Merkel Cell Carcinoma, demyelinating disorders, cerebrovascular accident, interstitial lung disease, pulmonary embolism, Stevens Johnson Syndrome, cutaneous vasculitis, erythema multiforme, new or worsening psoriasis, alopecia, lichenoid skin reaction, systemic vasculitis, deep vein thrombosis.
Pharmacology
Mirikizumab-mrkz is a humanized IgG4 monoclonal antibody that selectively binds to the p19 subunit of IL-23, inhibiting its interaction with the IL-23 receptor and suppressing downstream pro-inflammatory cytokine and chemokine release involved in mucosal inflammation.
Adalimumab is a recombinant human IgG1 monoclonal antibody that binds specifically to TNF-alpha, blocking its interaction with the p55 and p75 cell surface TNF receptors and inhibiting TNF-mediated inflammatory and immune responses, including modulation of adhesion molecules responsible for leukocyte migration.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Omvoh
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
Humira
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (0/12)
UnitedHealthcare
Omvoh
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (0/8) · Qty limit (0/8)
Humira
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (6/8) · Qty limit (0/8)
Humana
Omvoh
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (1/3)
Humira
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$5/fillfill
Omvoh Savings Program - Covered benefitCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Final cost depends on formulary coverage
$5/momo
Humira Complete Savings CardCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Final cost depends on formulary coverage
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.